News Home

Is Canopy Growth Corp (CGC) a Good Choice in Drug Manufacturers - Specialty & Generic Friday?

Friday, August 19, 2022 09:56 AM | InvestorsObserver Analysts
Is Canopy Growth Corp (CGC) a Good Choice in Drug Manufacturers - Specialty & Generic Friday?

The 31 rating InvestorsObserver gives to Canopy Growth Corp (CGC) stock puts it near the middle of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 58 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, CGC’s 31 overall rating means the stock scores better than 31 percent of all stocks.

Overall Score - 31
CGC has an Overall Score of 31. Find out what this means to you and get the rest of the rankings on CGC!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Canopy Growth Corp Stock Today?

Canopy Growth Corp (CGC) stock is trading at $3.73 as of 9:51 AM on Friday, Aug 19, a decline of -$0.08, or -2.1% from the previous closing price of $3.81. The stock has traded between $3.67 and $3.83 so far today. Volume today is light. So far 789,488 shares have traded compared to average volume of 14,649,095 shares. Click Here to get the full Stock Report for Canopy Growth Corp stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App